Literature DB >> 9365190

Regulation of aromatase activity within the breast.

W R Miller1, P Mullen, P Sourdaine, C Watson, J M Dixon, J Telford.   

Abstract

Local oestrogen biosynthesis within the breast can be highly variable, in vitro aromatase activity both in breast cancers and mammary adipose tissue displaying over a 40-fold range between the highest and lowest levels. Evidence is presented to show that: (i) transcriptional activity may influence oestrogen biosynthesis within breast cancers in that both aromatase mRNA and STAT nuclear binding are correlated positively to in vitro aromatase activity; (ii) the local presence of cancer may enhance aromatase activity in particulate fractions and primary fibroblast cultures from mammary adipose tissue; (iii) tumour extracts and breast cyst fluids may induce aromatase in cultured fibroblasts, the active principles responsible for these effects being incompletely defined (although the combination of interleukin (IL)-6 and its soluble receptor dramatically enhances aromatase activity, it is unclear whether this particular cytokine system can account for the stimulatory effects of breast extracts and fluids); (iv) the aromatase activities in both breast cancer and adipose tissues are susceptible to classical aromatase inhibitors such as aminoglutethimide and 4-hydroxyandrostenedione (and to newer inhibitors such as CGS16949 and CGS20267 at low nanomolar concentrations) but reduced sensitivity to 4-hydroxyandrostenedione may be observed in certain breast cancers. These findings may have important implications for the development and progression of hormone-dependent cancers within the breast.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365190

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  12 in total

1.  Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.

Authors:  Maryam B Lustberg; Stephen P Povoski; Weiqiang Zhao; Rebecca M Ziegler; Yasuro Sugimoto; Amy S Ruppert; Amy M Lehman; Donna R Shiels; Ewa Mrozek; Bhuvaneswari Ramaswamy; Rachel M Layman; Robert W Brueggemeier; Charles L Shapiro
Journal:  Clin Breast Cancer       Date:  2011-05-19       Impact factor: 3.225

2.  Induction of quinone reductase by tamoxifen or DPN protects against mammary tumorigenesis.

Authors:  Nirmala Krishnamurthy; Yanduan Hu; Sandra Siedlak; Yong Qiu Doughman; Michiko Watanabe; Monica M Montano
Journal:  FASEB J       Date:  2012-06-14       Impact factor: 5.191

3.  Growth factor signaling enhances aromatase activity of breast cancer cells via post-transcriptional mechanisms.

Authors:  Bin Su; Cynthie Wong; Yanyan Hong; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2010-11-26       Impact factor: 4.292

4.  Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer.

Authors:  Edgar S Díaz-Cruz; Yasuro Sugimoto; G Ian Gallicano; Robert W Brueggemeier; Priscilla A Furth
Journal:  Cancer Res       Date:  2011-08-15       Impact factor: 12.701

Review 5.  Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.

Authors:  Paul E Goss; Kathrin Strasser
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells.

Authors:  Yu Zheng; Bo Yu; Wanlop Weecharangsan; Longzhu Piao; Michael Darby; Yicheng Mao; Rumiana Koynova; Xiaojuan Yang; Hong Li; Songlin Xu; L James Lee; Yasuro Sugimoto; Robert W Brueggemeier; Robert J Lee
Journal:  Int J Pharm       Date:  2010-02-13       Impact factor: 5.875

Review 7.  Letrozole. A review of its use in postmenopausal women with advanced breast cancer.

Authors:  H M Lamb; J C Adkins
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

8.  Aromatase and COX in breast cancer: enzyme inhibitors and beyond.

Authors:  Robert W Brueggemeier; Bin Su; Yasuro Sugimoto; Edgar S Díaz-Cruz; Danyetta D Davis
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-25       Impact factor: 4.292

9.  Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.

Authors:  Young H Ju; Daniel R Doerge; Kellie A Woodling; James A Hartman; Jieun Kwak; William G Helferich
Journal:  Carcinogenesis       Date:  2008-07-16       Impact factor: 4.944

10.  Breast weight and hormone receptor status in women with breast cancer.

Authors:  M Salhab; W Al Sarakbi; K Mokbel
Journal:  Int Semin Surg Oncol       Date:  2005-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.